Table 5.
Correlation analysis of SCC antigen levels with progression-free survival of patients with cervical squamous cell carcinoma
| Variable | Mean survival times (months) | χ2 | P |
|---|---|---|---|
| SCC antigen levels before chemotherapy | 0.054 | 0.817 | |
| NACT group (n = 63) | 38.02 (34.43, 41.61) | ||
| Conventional group (n = 39) | 31.99 (29.25, 34.74) | ||
| NACT group | 0.0002 | 0.988 | |
| Chemotherapy-insensitive group (n = 32) | 36.34 (31.50, 41.19) | ||
| Chemotherapy-sensitive group (n = 31) | 38.09 (33.07, 43.12) | ||
| SCC antigen levels in NACT group before chemotherapy | 12.148 | < 0.001 | |
| < 4.55 (n = 29) | NA a | ||
| ≥ 4.55 (n = 34) | NA a | ||
| SCC antigen levels ≥4.55 before chemotherapy | 3.256 | 0.071 | |
| NACT group (n = 34) | 30.21 (24.74, 35.67) | ||
| Conventional group (n = 22) | 31.27 (28.21, 34.34) | ||
| SCC antigen levels in NACT group after the first chemotherapy | 13.954 | < 0.001 | |
| < 2.70 (n = 39) | 43.34 (41.09, 45.58) | ||
| ≥ 2.70 (n = 24) | 24.74 (18.80, 30.68) |
a, in NACT group before chemotherapy, when SCC antigen levels < 4.55 ng/mL, 29 patients were survival and it is impossible to calculate the survival times of patients